US dermatology top boss moves to Danish biotech firm

Draupnir Bio, which landed DKK 225m from four venture funds last year, will soon get a new boss in the form of Andrew Hotchkiss, who has previously worked as the CEO of Dermira. Further, the company is upgrading its board with a former Abbvie and Amgen executive.
Draupnir Bio CSO Simon Glerup | Photo: Draupnir Bio / PR
Draupnir Bio CSO Simon Glerup | Photo: Draupnir Bio / PR
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN

Danish biotech company, which raised DKK 225m (USD 36.2m) in capital in 2019  from a series of European venture funds including Novo Seeds will be changing its CEO.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading